Endonovo Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-959.5K | $-2.9M | $-1.9M | $-94.1K | $-69.4K |
| Depreciation & Amortization | $15.7K | $12.0K | $37.0K | $979 | $964 |
| Depreciation | — | — | $1.1K | $980 | $964 |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Net Cash from Operating Activities | $-909.3K | $-257.4K | $-284.9K | $-50.4K | $8.5K |
| Investing Activities | |||||
| Capital Expenditures | $0 | — | — | — | — |
| Business Acquisitions | — | $-4.1K | $53.0K | — | — |
| Net Cash from Investing Activities | $0 | $4.1K | $11.4K | — | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $907.0K | $255.7K | $287.7K | $85.3K | $-23.0K |
| Net Change in Cash | $-2.3K | $2.5K | $-8.6K | $34.9K | $-14.5K |
| Free Cash Flow | $-909.3K | — | — | — | — |